Bibliografías temáticas / Sch56002

Índice

  1. Artículos de revistas
  2. Tesis
  3. Libros

Literatura académica sobre el tema "Sch56002"

Autor: Grafiati
Publicado: 25 de julio de 2024
Última modificación: 31 de julio de 2025

Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros

Elija tipo de fuente:

Consulte las listas temáticas de artículos, libros, tesis, actas de conferencias y otras fuentes académicas sobre el tema "Sch56002".

Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.

También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.

Artículos de revistas sobre el tema "Sch56002"

1

Perfect, J. R., G. M. Cox, R. K. Dodge, and W. A. Schell. "In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans." Antimicrobial Agents and Chemotherapy 40, no. 8 (1996): 1910–13. http://dx.doi.org/10.1128/aac.40.8.1910.

Texto completo
Resumen
Multiple isolates of Cryptococcus neoformans were tested to compare the in vitro activity of a new triazole, SCH56592, with those of amphotericin B, fluconazole, and itraconazole, MICs of each drug were determined, and minimum fungicidal concentrations of SCH56592 and amphotericin B were measured. MICs of SCH56592 were lower than those of amphotericin B and fluconazole but not those of itraconazole. Minimum fungicidal concentrations of SCH56592 were lower than those of amphotericin B. SCH56592 in the presence of human serum produces an in vitro fungicidal effect for Cryptococcus neoformans. Th
Los estilos APA, Harvard, Vancouver, ISO, etc.
2

Graybill, John R., Rosie Bocanegra, Laura K. Najvar, David Loebenberg, and Mike F. Luther. "Granulocyte Colony-Stimulating Factor and Azole Antifungal Therapy in Murine Aspergillosis: Role of Immune Suppression." Antimicrobial Agents and Chemotherapy 42, no. 10 (1998): 2467–73. http://dx.doi.org/10.1128/aac.42.10.2467.

Texto completo
Resumen
ABSTRACT Outbred ICR mice were immune suppressed either with hydrocortisone or with 5-fluorouracil and were infected intranasally withAspergillus fumigatus. Beginning 3 days before infection some groups of mice were given recombinant human granulocyte colony-stimulating factor (G-CSF), SCH56592 (an antifungal triazole), or both. Corticosteroid-pretreated mice responded to SCH56592 and had reduced counts in lung tissue and prolonged survival. In these mice, G-CSF strongly antagonized the antifungal activity of SCH56592. Animals treated with both agents developed large lung abscesses with polymo
Los estilos APA, Harvard, Vancouver, ISO, etc.
3

Galgiani, J. N., and M. L. Lewis. "In vitro studies of activities of the antifungal triazoles SCH56592 and itraconazole against Candida albicans, Cryptococcus neoformans, and other pathogenic yeasts." Antimicrobial Agents and Chemotherapy 41, no. 1 (1997): 180–83. http://dx.doi.org/10.1128/aac.41.1.180.

Texto completo
Resumen
We investigated the effects of various assay conditions on the activities of two antifungal drugs, SCH56592 and itraconazole, against seven species of fungi by the broth macrodilution testing procedure proposed by the National Committee for Clinical Laboratory Standards (NCCLS). For both drugs, which are insoluble in water, the concentration and type of solubilizing agent produced differences in drug activity. Starting inoculum size differences from 10(2) to 10(5) yeast cells per ml resulted in approximately a fourfold effect on the MIC of both drugs, but other significant differences were not
Los estilos APA, Harvard, Vancouver, ISO, etc.
4

Espinel-Ingroff, Ana. "Comparison of In Vitro Activities of the New Triazole SCH56592 and the Echinocandins MK-0991 (L-743,872) and LY303366 against Opportunistic Filamentous and Dimorphic Fungi and Yeasts." Journal of Clinical Microbiology 36, no. 10 (1998): 2950–56. http://dx.doi.org/10.1128/jcm.36.10.2950-2956.1998.

Texto completo
Resumen
The in vitro antifungal activities of SCH56592, MK-0991, and LY303366 against 83 isolates of Acremonium strictum,Aspergillus flavus, Aspergillus fumigatus,Aspergillus terreus, Bipolaris spp.,Blastomyces dermatitidis, Cladophialophora bantiana, Fusarium oxysporum, Fusarium solani, Histoplasma capsulatum,Phialophora spp., Pseudallescheria boydii,Rhizopus arrhizus, Scedosporium prolificans, and Sporothrix schenckii were compared. The in vitro activities of these agents against 104 isolates of yeast pathogens ofCandida spp., Cryptococcus neoformans, andTrichosporon beigelii were also compared. MIC
Los estilos APA, Harvard, Vancouver, ISO, etc.
5

Graybill, J. R., R. Bocanegra, L. K. Najvar, M. F. Luther, and D. Loebenberg. "SCH56592 treatment of murine invasive aspergillosis." Journal of Antimicrobial Chemotherapy 42, no. 4 (1998): 539–42. http://dx.doi.org/10.1093/jac/42.4.539.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
6

Kirkpatrick, William R., Robert K. McAtee, Annette W. Fothergill, David Loebenberg, Michael G. Rinaldi, and Thomas F. Patterson. "Efficacy of SCH56592 in a Rabbit Model of Invasive Aspergillosis." Antimicrobial Agents and Chemotherapy 44, no. 3 (2000): 780–82. http://dx.doi.org/10.1128/aac.44.3.780-782.2000.

Texto completo
Resumen
ABSTRACT SCH56592 (SCH) was evaluated in an immunosuppressed rabbit model of invasive aspergillosis. SCH was more effective than similar doses of itraconazole and as effective as amphotericin B in the clearance ofAspergillus spp. from tissues. Compared with controls, SCH regimens reduced mortality, improved survival, and significantly reduced tissue colony counts.
Los estilos APA, Harvard, Vancouver, ISO, etc.
7

Hossain, Mohammad Ashraf, Shigefumi Maesaki, Kotaro Mitsutake, et al. "In-vitro and in-vivo activities of SCH56592 against Cryptococcus neoformans." Journal of Antimicrobial Chemotherapy 44, no. 6 (1999): 827–29. http://dx.doi.org/10.1093/jac/44.6.827.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
8

Espinel-Ingroff, A. "Germinated and Nongerminated Conidial Suspensions for Testing of Susceptibilities of Aspergillus spp. to Amphotericin B, Itraconazole, Posaconazole, Ravuconazole, and Voriconazole." Antimicrobial Agents and Chemotherapy 45, no. 2 (2001): 605–7. http://dx.doi.org/10.1128/aac.45.2.605-607.2001.

Texto completo
Resumen
ABSTRACT The effect of germinated and nongerminated conidia ofAspergillus spp. on the fungistatic (National Committee for Clinical Laboratory Standards document M38-P) and fungicidal activities (MICs and minimal fungicidal concentrations [MFCs] respectively) of amphotericin B, itraconazole, posaconazole (SCH56592), ravuconazole (BMS-207147), and voriconazole was evaluated. MFCs were the lowest drug dilutions that showed fewer than three colonies (99.9% killing). Overall, the MICs (0.12 to 4 μg/ml) and MFCs (0.5 to >8 μg/ml) of all of the agents tested with both inocula were the same or with
Los estilos APA, Harvard, Vancouver, ISO, etc.
9

Manavathu, Elias K., Jessica Cutright, and Pranatharthi H. Chandrasekar. "Comparative Study of Susceptibilities of Germinated and Ungerminated Conidia of Aspergillus fumigatus to Various Antifungal Agents." Journal of Clinical Microbiology 37, no. 3 (1999): 858–61. http://dx.doi.org/10.1128/jcm.37.3.858-861.1999.

Texto completo
Resumen
Conidia are used as inocula for the in vitro susceptibility testing of Aspergillus fumigatus. Since the MIC is defined on the basis of visible mycelial growth, conidia should germinate and produce sporelings (germinated conidia) for monitoring of the growth inhibition and fungicidal activity of a drug. If a compound is capable of inhibiting germination of conidia while affecting or not affecting the growth of the organism, the MIC obtained will be the concentration of the drug required for the inhibition of conidial germination but not necessarily that required for inhibition of the growth of
Los estilos APA, Harvard, Vancouver, ISO, etc.
10

Yildiran, S. T., A. W. Fothergill, D. A. Sutton, and M. G. Rinaldi. "In vitrosusceptibilities of cerebrospinal fluid isolates ofCryptococcus neoformanscollected during a ten-year period against fluconazole, voriconazole and posaconazole (SCH56592)." Mycoses 45, no. 9-10 (2002): 378–83. http://dx.doi.org/10.1046/j.1439-0507.2002.00765.x.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.

Tesis sobre el tema "Sch56002"

1

Walker, Edward Richard. "Studies towards the total synthesis of SCH56036." Thesis, Imperial College London, 2004. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.415665.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.

Libros sobre el tema "Sch56002"

1

Oogenesis. Springer London, Limited, 2016.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
2

Oogenesis. Springer London, Limited, 2012.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
3

Otruba, Kathy. SCH5620 Desktop Embedded Controller with Fan Control, Hardware Monitoring and PECI - Product Brief. Microchip Technology Incorporated, 2014.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
Ofrecemos descuentos en todos los planes premium para autores cuyas obras están incluidas en selecciones literarias temáticas. ¡Contáctenos para obtener un código promocional único!

Pasar a la bibliografía